Summary
This webcast with PRA Health Sciences' Jacinta Aniagolu-Johnson (Senior Director, Safety and Risk Management) explores how a well defined signal process adds critical value to risk assessment and risk management.
You may also be interested in:
Case Study
PRA Leads Novel Multiple Myeloma Drug Development
PRA Health Sciences supported 2 multiple myeloma clinical trials, a Phase III and a “rollover,” for a large biotech client. This management contract…
View Resource
White Paper
Local Representation: What Clinical Trial Sponsors Need to Know
In this white paper, best practices are described as well as required Sponsor/Local Representative agreement areas. It is important that major…
View Resource
resource
PRA Health Sciences To Report Fourth Quarter 2014 Earnings
PRA Health Sciences, Inc. (NASDAQ: PRAH) will release its fourth quarter and year end 2014 results after the market closes on Wednesday, February 18,…
View Resource
View all related content and resources for Pharmacovigilance
Explore Insights